Collateral damage: the conundrum of drug safety E. A. M. Gale Editorial 18 August 2009 Pages: 1975 - 1982
Type 1 and type 2 diabetes—chalk and cheese? K. R. OwenM. I. McCarthy Commentary 01 August 2009 Pages: 1983 - 1986
The insulin glargine dilemma: an opportunity for the diabetes community? M. StumvollP. P. Nawroth Commentary 14 August 2009 Pages: 1987 - 1989
Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses D. S. LassersonP. GlasziouA. J. Farmer Meta-analysis 31 July 2009 Pages: 1990 - 2000
Cardiovascular risk assessment scores for people with diabetes: a systematic review P. ChamnanR. K. SimmonsN. J. Wareham Review Open access 24 July 2009 Pages: 2001 - 2014
Novel pharmacological approaches to combat obesity and insulin resistance: targeting skeletal muscle with ‘exercise mimetics’ A. L. CareyB. A. Kingwell Review 23 June 2009 Pages: 2015 - 2026
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial J. W. J. BeulensA. Patelon behalf of the AdRem* project team and ADVANCE management committee Article 25 July 2009 Pages: 2027 - 2036
Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial D. KoyaM. Hanedaon behalf of the Low-Protein Diet Study Group Article Open access 04 August 2009 Pages: 2037 - 2045
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial D. Russell-JonesA. Vaagon behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group Article Open access 14 August 2009 Pages: 2046 - 2055
Associations between vascular co-morbidities and depression in insulin-naive diabetes patients: the DIAZOB Primary Care Diabetes study B. KoopmansF. PouwerV. J. M. Pop Article Open access 09 August 2009 Pages: 2056 - 2063
Height growth velocity, islet autoimmunity and type 1 diabetes development: the Diabetes Autoimmunity Study in the Young M. M. LambX. YinJ. M. Norris Article 23 June 2009 Pages: 2064 - 2071
Is islet autoimmunity related to insulin sensitivity or body weight in children of parents with type 1 diabetes? C. WinklerS. MarienfeldA.-G. Ziegler Article 30 July 2009 Pages: 2072 - 2078
Insulin resistance, beta cell dysfunction and visceral adiposity as predictors of incident diabetes: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study A. J. G. HanleyL. E. WagenknechtS. M. Haffner Article 31 July 2009 Pages: 2079 - 2086
Incidence of insulin-requiring diabetes in the US military E. D. GorhamE. Barrett-ConnorC. Ricordi Short Communication Open access 24 July 2009 Pages: 2087 - 2091
Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle Générale de l’Education Nationale (E3N) cohort B. de Lauzon-GuillainA. FournierF. Clavel-Chapelon Article 23 July 2009 Pages: 2092 - 2100
Circulating IL-18 and the risk of type 2 diabetes in women M. F. HivertQ. SunF. B. Hu Article 08 August 2009 Pages: 2101 - 2108
No association of multiple type 2 diabetes loci with type 1 diabetes S. M. RajJ. M. M. HowsonJ. A. Todd Article Open access 20 May 2009 Pages: 2109 - 2116
Circulating β-carotene levels and type 2 diabetes—cause or effect? J. R. B. PerryL. FerrucciT. M. Frayling Short Communication 07 August 2009 Pages: 2117 - 2121
A variant in the G6PC2/ABCB11 locus is associated with increased fasting plasma glucose, increased basal hepatic glucose production and increased insulin release after oral and intravenous glucose loads C. S. RoseN. GrarupT. Hansen Article 08 August 2009 Pages: 2122 - 2129
Perinatal survivin is essential for the establishment of pancreatic beta cell mass in mice X. WuL. WangM. Woo Article 31 July 2009 Pages: 2130 - 2141
Effects of glucokinase activators GKA50 and LY2121260 on proliferation and apoptosis in pancreatic INS-1 beta cells P. WeiM. ShiJ. D. Fraser Article 30 July 2009 Pages: 2142 - 2150
Regulation of insulin gene expression by cytokines and cell–cell interactions in mouse medullary thymic epithelial cells D. LeviC. Polychronakos Article 16 July 2009 Pages: 2151 - 2158
Metabolic effects of diets differing in glycaemic index depend on age and endogenous glucose-dependent insulinotrophic polypeptide in mice F. IskenM. O. WeickertA. F. Pfeiffer Article 31 July 2009 Pages: 2159 - 2168
Impaired regulation of the TNF-α converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans A. MonroyS. KamathF. Folli Article 25 July 2009 Pages: 2169 - 2181
Regulation of skeletal muscle sucrose, non-fermenting 1/AMP-activated protein kinase-related kinase (SNARK) by metabolic stress and diabetes A. RuneM. E. OslerJ. R. Zierath Article Open access 04 August 2009 Pages: 2182 - 2189
Leptin prevents the metabolic effects of adiponectin in L6 myotubes X. FangJ. FetrosG. Sweeney Article 28 July 2009 Pages: 2190 - 2200
Constitutive expression of suppressor of cytokine signalling-3 in skeletal muscle leads to reduced mobility and overweight in mice P. LebrunE. CognardE. Van Obberghen Article 12 August 2009 Pages: 2201 - 2212
Retinal vessel calibre and micro- and macrovascular complications in type 1 diabetes J. GrauslundL. HodgsonT. Y. Wong Short Communication 18 July 2009 Pages: 2213 - 2217
C-peptide is internalised in human endothelial and vascular smooth muscle cells via early endosomes P. LuppiX. GengM. Trucco Article 07 August 2009 Pages: 2218 - 2228
Glucose variability does not contribute to the development of peripheral and autonomic neuropathy in type 1 diabetes: data from the DCCT S. E. SiegelaarE. S. KilpatrickJ. H. DeVries Research Letter Open access 12 August 2009 Pages: 2229 - 2232
The longest ever randomised controlled trial of insulin glargine: study design and HbA1c findings C. J. Currie Letter 07 August 2009 Pages: 2234 - 2235
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Reply to Chantelau E [letter] and Currie CJ [letter] J. RosenstockV. FonsecaM. Davis Letter Open access 25 August 2009 Pages: 2236 - 2239
Does vitamin D status contribute to caveolin-1-mediated insulin sensitivity in skeletal muscle? B. J. Boucher Letter 12 August 2009 Pages: 2240 - 2240
Does vitamin D status contribute to caveolin-1-mediated insulin sensitivity in skeletal muscle? Reply to Boucher BJ [letter] Y. S. OhH.-S. JunS. C. Park Letter 10 August 2009 Pages: 2241 - 2243
Copper chelation as a potential treatment for left-ventricular hypertrophy in type 2 diabetes S. J. L. BakkerG. NavisR. O. B. Gans Letter Open access 19 August 2009 Pages: 2244 - 2244